Sclerostin: therapeutic horizons based upon its actions.

  title={Sclerostin: therapeutic horizons based upon its actions.},
  author={Aline M. G. Costa and John P. Bilezikian},
  journal={Current osteoporosis reports},
  volume={10 1},
Inactivating mutations of the SOST gene cause a reduction in sclerostin levels and are associated with high bone mass. The clinical phenotypes, sclerosteosis and van Buchem's disease, were described in 1950s. Much later, it was learned that both diseases are due to loss-of-function mutations in the SOST gene. As a regulator of an important osteoanabolic pathway, Wnt, inactivation of SOST leads to a stimulation of the pathway it regulates. The high bone mass in patients with either sclerosteosis… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 22 extracted citations

Similar Papers

Loading similar papers…